Across TCGA pan-cancer cohorts, IGLV2-11 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated IGLV2-11 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher IGLV2-11 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated IGLV2-11 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

UCEC, CCRCC, and HNSC are the cancer types where IGLV2-11 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Quartile	All	0.742	1.000	.002	60	view →
CCRCC	DFS	Median	III,IV	0.894	0.521	.002	45	view →
HNSC	OS	Median	II,III,IV	0.953	1.000	.019	12	view →
GBM	DFS	Median	All	0.530	0.232	<.001	10	view →
LUAD	DFS	Tertile	II,III,IV	0.836	0.510	.021	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: IGLV2-11 tumor-vs-normal RNA expression · all IGLV2-11 data types